Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial
Primary Purpose
Diabetic Macular Edema
Status
Unknown status
Phase
Phase 3
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Triamcinolone, Bevacizumab
Sponsored by
About this trial
This is an interventional treatment trial for Diabetic Macular Edema focused on measuring Cystoid macular edema, Diabetic macular edema, Hard exudates, Intravitreal bevacizumab, Intravitreal triamcinolone, Macular thickness
Eligibility Criteria
Inclusion Criteria: Cases with clinically significant macular edema (CSME) with persistent retinal thickening after initial or supplemental macular photocoagulation Exclusion Criteria: Monocularity, History of vitrectomy, Glaucoma or ocular hypertension, Significant media opacity, Existence of traction on the macula
Sites / Locations
- Hamid Ahmadieh, MD
Outcomes
Primary Outcome Measures
Visual acuity
Central macular thickness
Secondary Outcome Measures
Cataract progression
Intraocular pressure
Anterior chamber reaction
Full Information
NCT ID
NCT00370422
First Posted
August 30, 2006
Last Updated
March 12, 2007
Sponsor
Shahid Beheshti University of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT00370422
Brief Title
Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2005
Overall Recruitment Status
Unknown status
Study Start Date
November 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2006 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Shahid Beheshti University of Medical Sciences
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to compare the efficacy and safety of intravitreal injection of bevacizumab alone versus bevacizumab combined with triamcinolone for treatment of refractory diabetic macular edema.
Detailed Description
According to the early treatment diabetic retinopathy study (ETDRS), the treatment of choice for diabetic macular edema is laser therapy, which may be neither effective nor curative in some patients. Corticosteroids may have a beneficial effect on diabetic macular edema. Other newly introduced medications for macular edematous lesions are anti-VEGF vascular endothelial growth factor)drugs. In this randomized, sham-controlled, multicenter, three-arm clinical trial,we try to evaluate the safety and efficacy of intravitreal bevacizumab alone and in combination with intravitreal triamcinolone in the treatment of refractory diabetic macular edema.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Macular Edema
Keywords
Cystoid macular edema, Diabetic macular edema, Hard exudates, Intravitreal bevacizumab, Intravitreal triamcinolone, Macular thickness
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Single
Allocation
Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Triamcinolone, Bevacizumab
Primary Outcome Measure Information:
Title
Visual acuity
Title
Central macular thickness
Secondary Outcome Measure Information:
Title
Cataract progression
Title
Intraocular pressure
Title
Anterior chamber reaction
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Cases with clinically significant macular edema (CSME) with persistent retinal thickening after initial or supplemental macular photocoagulation
Exclusion Criteria:
Monocularity,
History of vitrectomy,
Glaucoma or ocular hypertension,
Significant media opacity,
Existence of traction on the macula
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hamid Ahmadieh, MD
Organizational Affiliation
Ophthalmic Research Center of Shaheed Beheshti Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hamid Ahmadieh, MD
City
Tehran
ZIP/Postal Code
16666
Country
Iran, Islamic Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
17917738
Citation
Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, Soheilian M, Keshavarzi G, Mohebbi MR. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2008 Apr;246(4):483-9. doi: 10.1007/s00417-007-0688-0. Epub 2007 Oct 5.
Results Reference
derived
Learn more about this trial
Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial
We'll reach out to this number within 24 hrs